(R,S)-1,4,5,7-Tetrahydro-2-methyl-5-oxo-4-<2-(trifluormethyl)phenyl>furo<3,4-b>pyridin-3-carbonsaeuremethylester | 85825-31-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R,S)-1,4,5,7-Tetrahydro-2-methyl-5-oxo-4-<2-(trifluormethyl)phenyl>furo<3,4-b>pyridin-3-carbonsaeuremethylester
• 英文别名: CAS 85825-31-6；Methyl 2-methyl-4-(2-trifluoromethylphenyl)-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate；methyl 2-methyl-5-oxo-4-[2-(trifluoromethyl)phenyl]-4,7-dihydro-1H-furo[3,4-b]pyridine-3-carboxylate
• CAS: 85825-31-6
• 化学式: C₁₇H₁₄F₃NO₄
• 分子量: 353.298
• InChiKey: YQNJWPJROXUEHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (R,S)-1,4,5,7-Tetrahydro-2-methyl-5-oxo-4-<2-(trifluormethyl)phenyl>furo<3,4-b>pyridin-3-carbonsaeuremethylester 在 manganese(IV) oxide 作用下， 以 甲苯 为溶剂， 以66%的产率得到5,7-Dihydro-2-methyl-5-oxo-4-<2-(trifluormethyl)phenyl>-furo<3,4-b>pyridin-3-carbonsaeuremethylester
  参考文献：
  名称：

  来自 Bay-K-8644 的稠合内酯和 Hantzsch 合成的二氢吡啶副产物

  摘要：

  Bay - K - 8644 (1) 与溴化吡啶鎓过溴化物 (PBPB) 反应生成稠合的 1,4 - 二氢吡啶 (DHP) 内酯 7 和吡啶鎓化合物 8；3-吡啶醇 10 和 11 是由它在 UV A 光下形成的。PBPB 可用于从二酯 1,4-DHP 2 中分离出单内酯 12、双内酯 13 和二溴甲基衍生物 14。1,2-DHP 4 异构体与 1 仅产生氧化产物 17 与 PBPB，而二酯 1,2-DHP 5 除吡啶 (Py) 18 外导致稠合的 1,2-DHP-内酯 19 和 24 . 溶剂分解从 24 得到 25。所有 DHP 都脱水成相应的吡啶。DHP / Py 系统的半波电位由阳极氧化决定，讨论了它们对结构参数的依赖性。

  DOI：

  10.1002/ardp.2503241111
• 作为产物：
  描述：

  1,4-二氢-2,6-二甲基-4-[O-(三氟甲基)苯基]-3,5-吡啶二甲酸二甲酯 在 吡啶 、 pyridinium hydrobromide perbromide 作用下， 以 氯仿 为溶剂， 以56%的产率得到(R,S)-1,4,5,7-Tetrahydro-2-methyl-5-oxo-4-<2-(trifluormethyl)phenyl>furo<3,4-b>pyridin-3-carbonsaeuremethylester
  参考文献：
  名称：

  Facile Conversion of Hantzsch Type 4-Ary1-2,6-dimethyl-1,4-dihydropyridine-3,5-carboxylates into 4-Aryl-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylates

  摘要：

  DOI：

  10.1055/s-1984-30917

文献信息

• METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS
  申请人：Novartis AG

  公开号：US20210387995A1

  公开（公告）日：2021-12-16

  The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.

  本公开提供了一种根据公式(I)的化合物或其药物可接受的盐，作为Cav1.2激活剂，用于治疗精神分裂症、双相情感障碍、重性抑郁障碍、物质使用障碍、多动症、费伦-麦克德米德综合症、孤独症谱系障碍、多发性硬化症、额颞叶痴呆、阿尔茨海默病、布鲁加达综合症、短QT综合症和早期复极化综合症。
• Novel 1-alkyl-substituted 1,4-dihydropyridinelactone anti-diabetics
  申请人：Bayer Aktiengesellschaft

  公开号：US05026714A1

  公开（公告）日：1991-06-25

  Novel blood sugar-lowering dihydropyridinelactones of the formula ##STR1## in which R represents halogen, C.sub.1 -C.sub.10 -alkyl, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.10 -alkylthio, C.sub.1 -C.sub.10 -alkylsulphinyl, C.sub.1 -C.sub.10 -alkylsulphonyl, cyano, C.sub.1 -C.sub.6 - mono- or polyfluoroalkyl, C.sub.1 -C.sub.6 -mono- or polyfluoroalkoxy or nitro, R.sup.1 represents hydrogen, halogen or C.sub.1 -C.sub.10 -alkyl or C.sub.1 -C.sub.10 -alkoxy, R.sup.2 represents a C.sub.1 -C.sub.20 hydrocarbon radical which can optionally be interrupted or substituted, R.sup.3 represents hydrogen NH.sub.2, CHO, CN or a C.sub.1 -C.sub.6 hydrocarbon radical which can be interrupted in the chain, and R.sup.4 represents a C.sub.1 -C.sub.10 -alkyl or C.sub.2 -C.sub.10 -alkenyl radical which can optionally be interrupted or substituted with the proviso that R is not CF.sub.3 if R.sup.2 represents C.sub.2 H.sub.5.

  化学式为##STR1##的新型降血糖二氢吡啶内酯，其中R代表卤素、C.sub.1 -C.sub.10 -烷基、C.sub.1 -C.sub.10 -烷氧基、C.sub.1 -C.sub.10 -烷硫基、C.sub.1 -C.sub.10 -烷基砜基、C.sub.1 -C.sub.10 -烷基磺酰基、氰基、C.sub.1 -C.sub.6 单氟或多氟烷基、C.sub.1 -C.sub.6 单氟或多氟烷氧基或硝基，R.sup.1代表氢、卤素或C.sub.1 -C.sub.10 -烷基或C.sub.1 -C.sub.10 -烷氧基，R.sup.2代表可选择地被中断或取代的C.sub.1 -C.sub.20 碳氢基团，R.sup.3代表氢、NH.sub.2、CHO、CN或可在链中间断的C.sub.1 -C.sub.6 碳氢基团，R.sup.4代表可选择地被中断或取代的C.sub.1 -C.sub.10 -烷基或C.sub.2 -C.sub.10 -烯基基团，但要注意如果R.sup.2代表C.sub.2 H.sub.5，则R不是CF.sub.3。
• GOLDMANN, S.;BOSSERT, F.;BISCHOFF, H.;PETZINNA, D.;PULS, W.;SCHLOSSMANN, +
  作者：GOLDMANN, S.、BOSSERT, F.、BISCHOFF, H.、PETZINNA, D.、PULS, W.、SCHLOSSMANN, +

  DOI：——

  日期：——
• YOUNG, S. D., SYNTHESIS, BRD, 1984, N 7, 617-618
  作者：YOUNG, S. D.

  DOI：——

  日期：——
• METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS
  申请人：Novartis AG

  公开号：US20210395261A1

  公开（公告）日：2021-12-23

  The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Ca V 1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.